title: Chronic antagonism of the mineralocorticoid receptor ameliorates hypertension and end organ damage in a rodent model of salt-sensitive hypertension.
abstract: We investigated the effects of chronic mineralocorticoid receptor blockade with eplerenone on the development and progression of hypertension and end organ damage in Dahl salt-sensitive rats. Eplerenone significantly attenuated the progressive rise in systolic blood pressure (SBP) (204 ± 3 vs. 179±3 mmHg, p < 0.05), reduced proteinuria (605.5 ± 29.6 vs. 479.7 ± 26.1 mg/24h, p < 0.05), improved injury scores of glomeruli, tubules, renal interstitium, and vasculature in Dahl salt-sensitive rats fed a high-salt diet. These results demonstrate that mineralocorticoid receptor antagonism provides target organ protection and attenuates the development of elevated blood pressure (BP) in a model of salt-sensitive hypertension.
authors.affiliation: Department of Cardiovascular Diseases, Merck Research Laboratories, Rahway, New Jersey, USA. xiaoyan_zhou@merck.com
authors.forename: Xiaoyan
authors.initials: X
authors.lastname: Zhou
authors.forename: Martin F
authors.initials: MF
authors.lastname: Crook
authors.forename: Wanda
authors.initials: W
authors.lastname: Sharif-Rodriguez
authors.forename: Yonghua
authors.initials: Y
authors.lastname: Zhu
authors.forename: Zadok
authors.initials: Z
authors.lastname: Ruben
authors.forename: Yi
authors.initials: Y
authors.lastname: Pan
authors.forename: Olga
authors.initials: O
authors.lastname: Urosevic-Price
authors.forename: Li
authors.initials: L
authors.lastname: Wang
authors.forename: Amy M
authors.initials: AM
authors.lastname: Flattery
authors.forename: Gail
authors.initials: G
authors.lastname: Forrest
authors.forename: Daphne
authors.initials: D
authors.lastname: Szeto
authors.forename: Huawei
authors.initials: H
authors.lastname: Zhao
authors.forename: Sophie
authors.initials: S
authors.lastname: Roy
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Forrest
mesh_terms: D000450:Aldosterone / Q000097:blood; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002908:Chronic Disease; D003404:Creatinine / Q000097:blood; D004195:Disease Models, Animal; D018450:Disease Progression; D004573:Electrolytes / Q000097:blood; D000077545:Eplerenone; D006339:Heart Rate / Q000187:drug effects; D006977:Hypertension, Renal / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D007668:Kidney / Q000187:drug effects / Q000473:pathology / Q000502:physiology; D008297:Male; D000451:Mineralocorticoid Receptor Antagonists / Q000097:blood / Q000494:pharmacology*; D009929:Organ Size; D051381:Rats; D020303:Rats, Inbred Dahl; D018161:Receptors, Mineralocorticoid / Q000502:physiology; D017673:Sodium Chloride, Dietary / Q000494:pharmacology*; D013148:Spironolactone / Q000031:analogs & derivatives* / Q000097:blood / Q000494:pharmacology
chemical_list: D004573:Electrolytes; D000451:Mineralocorticoid Receptor Antagonists; D018161:Receptors, Mineralocorticoid; D017673:Sodium Chloride, Dietary; D013148:Spironolactone; D000450:Aldosterone; D000077545:Eplerenone; D003404:Creatinine